BR112015023394B8 - Sistema e complexo bioluminescente - Google Patents

Sistema e complexo bioluminescente

Info

Publication number
BR112015023394B8
BR112015023394B8 BR112015023394A BR112015023394A BR112015023394B8 BR 112015023394 B8 BR112015023394 B8 BR 112015023394B8 BR 112015023394 A BR112015023394 A BR 112015023394A BR 112015023394 A BR112015023394 A BR 112015023394A BR 112015023394 B8 BR112015023394 B8 BR 112015023394B8
Authority
BR
Brazil
Prior art keywords
luminescent
bioluminescent
complex
peptide
covalent
Prior art date
Application number
BR112015023394A
Other languages
English (en)
Portuguese (pt)
Other versions
BR112015023394A2 (pt
BR112015023394B1 (pt
Inventor
S Dixon Andrew
F Binkowski Brock
K Pulukkunat Dileep
Hicham Zegzouti
James Unch
Keith Wood
Lance Encell
Marie Schwinn
Mary Hall
Matthew Robers
Melanie Dart
Monika Wood
Nidhi Nath
Poncho Meisenheimer
Said Goueli
Subhanjan Mondal
Thomas Kirkland
Thomas Machleidt
Original Assignee
Promega Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Promega Corp filed Critical Promega Corp
Publication of BR112015023394A2 publication Critical patent/BR112015023394A2/pt
Publication of BR112015023394B1 publication Critical patent/BR112015023394B1/pt
Publication of BR112015023394B8 publication Critical patent/BR112015023394B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
    • G01N33/533—Production of labelled immunochemicals with fluorescent label
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0069—Oxidoreductases (1.) acting on single donors with incorporation of molecular oxygen, i.e. oxygenases (1.13)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43509—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from crustaceans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02—Linear peptides containing at least one abnormal peptide link
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/66—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving luciferase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
    • G01N33/542—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with steric inhibition or signal modification, e.g. fluorescent quenching
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/581—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with enzyme label (including co-enzymes, co-factors, enzyme inhibitors or substrates)
    • G—PHYSICS
    • G06—COMPUTING OR CALCULATING; COUNTING
    • G06Q—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES, NOT OTHERWISE PROVIDED FOR
    • G06Q30/00—Commerce
    • G06Q30/02—Marketing; Price estimation or determination; Fundraising
    • G06Q30/0283—Price estimation or determination
    • G—PHYSICS
    • G06—COMPUTING OR CALCULATING; COUNTING
    • G06Q—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES, NOT OTHERWISE PROVIDED FOR
    • G06Q30/00—Commerce
    • G06Q30/06—Buying, selling or leasing transactions
    • G06Q30/0601—Electronic shopping [e-shopping]
    • G06Q30/0631—Recommending goods or services
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04W—WIRELESS COMMUNICATION NETWORKS
    • H04W4/00—Services specially adapted for wireless communication networks; Facilities therefor
    • H04W4/02—Services making use of location information
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04W—WIRELESS COMMUNICATION NETWORKS
    • H04W4/00—Services specially adapted for wireless communication networks; Facilities therefor
    • H04W4/30—Services specially adapted for particular environments, situations or purposes
    • H04W4/35—Services specially adapted for particular environments, situations or purposes for the management of goods or merchandise
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04W—WIRELESS COMMUNICATION NETWORKS
    • H04W4/00—Services specially adapted for wireless communication networks; Facilities therefor
    • H04W4/30—Services specially adapted for particular environments, situations or purposes
    • H04W4/38—Services specially adapted for particular environments, situations or purposes for collecting sensor information
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/60—Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Business, Economics & Management (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Development Economics (AREA)
  • Accounting & Taxation (AREA)
  • Finance (AREA)
  • General Engineering & Computer Science (AREA)
  • Computer Networks & Wireless Communication (AREA)
  • Signal Processing (AREA)
  • Strategic Management (AREA)
  • General Business, Economics & Management (AREA)
  • Economics (AREA)
  • Marketing (AREA)
  • Theoretical Computer Science (AREA)
  • Epidemiology (AREA)
BR112015023394A 2013-03-15 2014-03-13 Sistema e complexo bioluminescente BR112015023394B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361791549P 2013-03-15 2013-03-15
US61/791,549 2013-03-15
PCT/US2014/026354 WO2014151736A1 (en) 2013-03-15 2014-03-13 Activation of bioluminescence by structural complementation

Publications (3)

Publication Number Publication Date
BR112015023394A2 BR112015023394A2 (pt) 2017-11-28
BR112015023394B1 BR112015023394B1 (pt) 2023-08-29
BR112015023394B8 true BR112015023394B8 (pt) 2023-09-26

Family

ID=51581027

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015023394A BR112015023394B8 (pt) 2013-03-15 2014-03-13 Sistema e complexo bioluminescente

Country Status (15)

Country Link
US (11) US9797890B2 (enExample)
EP (4) EP4169935A1 (enExample)
JP (4) JP6654557B2 (enExample)
KR (3) KR20150129721A (enExample)
CN (2) CN105143249A (enExample)
AU (3) AU2014236949C1 (enExample)
BR (1) BR112015023394B8 (enExample)
CA (1) CA2906063C (enExample)
DK (2) DK3783011T5 (enExample)
ES (2) ES2926463T3 (enExample)
IL (3) IL286816B (enExample)
PL (2) PL2970412T3 (enExample)
PT (2) PT3783011T (enExample)
SG (2) SG11201507306VA (enExample)
WO (1) WO2014151736A1 (enExample)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3783011T5 (da) 2013-03-15 2024-08-19 Promega Corp Aktivering af bioluminescens via strukturel komplementering
US11365402B2 (en) 2014-09-12 2022-06-21 Promega Corporation Internal protein tags
JP6814132B2 (ja) * 2014-09-12 2021-01-13 プロメガ コーポレイションＰｒｏｍｅｇａ Ｃｏｒｐｏｒａｔｉｏｎ 内部タンパク質タグ
EP3254113B1 (en) * 2015-02-05 2024-10-09 Promega Corporation Luciferase-based thermal shift assays
WO2017189751A1 (en) * 2016-04-26 2017-11-02 The University Of Utah Research Foundation Target-binding activated split reporter systems for analyte detection and related components and methods
JP7227901B2 (ja) 2016-10-20 2023-02-22 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ ボツリヌス神経毒素の活性を測定するためのインビトロアッセイ法及び細胞ベースのアッセイ法
US11579149B2 (en) * 2017-11-01 2023-02-14 Queen's University At Kingston Hippo pathway bioluminescent biosensor
JP7248693B2 (ja) * 2018-02-26 2023-03-29 テクニーシェ・ユニバーシタイト・アイントホーベン 溶液中の生物分子またはリガンドを検出し、定量化する生物発光バイオセンサー
EP4140991B1 (en) 2018-06-01 2024-05-15 Promega Corporation Inhibitors of oplophorus luciferase-derived bioluminescent complexes
US20200270586A1 (en) * 2018-06-12 2020-08-27 Promega Corporation Multipartite luciferase
US10962538B2 (en) 2018-06-14 2021-03-30 The Trustees Of Columbia University In The City Of New York Assays using arrestin recruitment and unmodified receptors
JP7447101B2 (ja) 2018-10-03 2024-03-11 プロメガ コーポレイション セレンテラジンならびにその類似体及び誘導体を安定化させるための組成物及び方法
EP3887830A2 (en) 2018-11-28 2021-10-06 Promega Corporation Reactive peptide labeling
US20200200765A1 (en) 2018-12-04 2020-06-25 Promega Corporation Broad spectrum gpcr binding agents
EP3941195A4 (en) 2019-03-20 2023-03-22 Promega Corporation PHOTOAFFINITY PROBES
WO2020210658A1 (en) * 2019-04-10 2020-10-15 Promega Corporation Compositions and methods for analyte detection using bioluminescence
US11360096B2 (en) 2019-05-16 2022-06-14 Duke University Complex BRET technique for measuring biological interactions
EP3986956A1 (en) 2019-06-24 2022-04-27 Promega Corporation Modified polyamine polymers for delivery of biomolecules into cells
DE102019127894B4 (de) * 2019-10-16 2022-05-12 Sensor-Instruments Entwicklungs- Und Vertriebs-Gmbh Produktkennzeichnungssystem und verfahren zur kennzeichnung eines produkts
EP4061853A4 (en) * 2019-11-22 2023-12-27 The Regents of the University of California SPLIT ENZYME SYSTEM TO DETECT SPECIFIC DNA IN LIVING CELLS
US12241839B2 (en) 2019-11-27 2025-03-04 Promega Corporation Multipartite luciferase peptides and polypeptides
JP7745550B2 (ja) 2019-12-10 2025-09-29 プロメガ コーポレイション 多官能性プローブを使用する生物発光検出用組成物及び生物発光検出方法
JP2023520359A (ja) 2020-03-25 2023-05-17 エラスムス・ユニヴァーシティ・メディカル・センター・ロッテルダム 放射性核種イメージングのためのレポーター系
US20230176057A1 (en) * 2020-05-11 2023-06-08 Chan Zuckerberg Biohub, Inc. Detection assay for sars-cov-2 virus
US20210363565A1 (en) 2020-05-22 2021-11-25 Promega Corporation Enhancement of kinase target engagement
JP2023540934A (ja) 2020-08-28 2023-09-27 プロメガ コーポレイション Ｒａｓタンパク質のターゲットエンゲージメントアッセイ
WO2022245922A1 (en) * 2021-05-18 2022-11-24 The Board Of Regents Of The University Of Texas System Poly-adp ribose (par) tracker optimized split-protein reassembly par detection reagents
JP2025515181A (ja) 2022-05-04 2025-05-13 プロメガ コーポレイション 伸長表面ループ領域を有する修飾デハロゲナーゼ
EP4519426A2 (en) 2022-05-04 2025-03-12 Promega Corporation Split modified dehalogenase variants
US20240060059A1 (en) 2022-05-04 2024-02-22 Promega Corporation Circularly permuted dehalogenase variants
WO2023215497A1 (en) 2022-05-04 2023-11-09 Promega Corporation Photoactivatable compounds and uses thereof
WO2024151471A1 (en) * 2023-01-09 2024-07-18 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services High-throughput assay based on ligand-biased structural dynamics response
WO2024217577A1 (zh) * 2023-04-21 2024-10-24 深圳琅技生命科技有限公司 一种肽以及含有该肽的发光复合物
US20240368565A1 (en) * 2023-05-04 2024-11-07 Promega Corporation Complementation-based tags and reporters for dual-modality labeling
WO2025064581A1 (en) * 2023-09-18 2025-03-27 The Brigham And Women’S Hospital, Inc. Biosensor platform for the rapid detection of analytes
WO2025158412A1 (en) 2024-01-26 2025-07-31 Biohaven Therapeutics Ltd. BIFUNCTIONAL DEGRADERS OF IgG4 IMMUNOGLOBULINS

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444879A (en) * 1981-01-29 1984-04-24 Science Research Center, Inc. Immunoassay with article having support film and immunological counterpart of analyte
US5914095A (en) 1989-04-07 1999-06-22 Salutar, Inc. Polychelants containg amide bonds
CA2146990A1 (en) 1992-10-14 1994-04-28 Robert A. Snow Chelating polymers
US5756688A (en) 1992-10-14 1998-05-26 Sterling Winthrop Inc. MR imaging compositions and methods
GB9503969D0 (en) 1995-02-28 1995-04-19 Sams Bernard Incrementing mechanism
CA2196496A1 (en) 1997-01-31 1998-07-31 Stephen William Watson Michnick Protein fragment complementation assay for the detection of protein-protein interactions
US5879739A (en) 1997-02-20 1999-03-09 Tower Semiconductor Ltd. Batch process for forming metal plugs in a dielectric layer of a semiconductor wafer
JP4613441B2 (ja) * 2000-04-26 2011-01-19 チッソ株式会社 新規ルシフェラーゼおよび発光蛋白質
DE60142761D1 (de) * 2000-04-26 2010-09-23 Chisso Corp Oplophorus Luciferase
US20040181830A1 (en) 2001-05-07 2004-09-16 Kovalic David K. Nucleic acid molecules and other molecules associated with plants and uses thereof for plant improvement
US7008642B1 (en) 2001-02-12 2006-03-07 Advanced Cardiovascular Systems, Inc. Compositions for achieving a therapeutic effect in an anatomical structure and methods of using the same
US7195884B2 (en) 2002-07-19 2007-03-27 Promega Corp. Methods and kits for transferases
AU2003283995A1 (en) * 2002-09-30 2004-04-19 Protein Design Labs, Inc. Efficient generation of stable expression cell lines through the use of scorable homeostatic reporter genes
US7237811B1 (en) * 2005-04-20 2007-07-03 Lawrence Barry G Casement window latch assembly
US20090149338A1 (en) 2005-09-30 2009-06-11 Hughes Thomas E System for detecting protein-protein interactions
US7601517B2 (en) 2006-01-10 2009-10-13 Stanford University Split protein self complementing fragments, systems, and methods of use thereof
WO2007132461A2 (en) 2006-05-11 2007-11-22 Ramot At Tel Aviv University Ltd. Classification of protein sequences and uses of classified proteins
US20090075313A1 (en) 2007-05-04 2009-03-19 Stanford University Split protein fragments, split protein systems, methods of making split protein systems, and methods of using split protein systems
CA2704226A1 (en) * 2007-11-01 2009-05-07 The Arizona Board Of Regents On Behalf Of The University Of Arizona Cell-free methods for detecting protein-ligand interctions
CA2705808A1 (en) * 2007-11-15 2009-05-22 Endocyte, Inc. Method of administering conjugates
WO2010090319A1 (ja) 2009-02-09 2010-08-12 チッソ株式会社 セレンテラジン類縁体及びその製造方法
JPWO2010119721A1 (ja) 2009-04-17 2012-10-22 独立行政法人産業技術総合研究所 超高輝度で安定な人工生物発光酵素
WO2010127368A1 (en) * 2009-05-01 2010-11-04 Promega Corporation Synthetic oplophorus luciferases with enhanced light output
EP2550529B1 (en) * 2010-03-23 2021-11-17 Iogenetics, LLC. Bioinformatic processes for determination of peptide binding
ES2567410T3 (es) 2010-11-02 2016-04-22 Promega Corporation Nuevos sustratos de coelenterazina y métodos de uso
US20150125438A1 (en) * 2012-07-20 2015-05-07 Sang Jae Kim Anti-Inflammatory Peptides and Composition Comprising the Same
CA2894435A1 (en) * 2012-12-12 2014-06-19 Promega Corporation Recognition of cellular target binding by a bioactive agent using intracellular bioluminescence resonance energy transfer
DK3783011T5 (da) 2013-03-15 2024-08-19 Promega Corp Aktivering af bioluminescens via strukturel komplementering
JP6814132B2 (ja) * 2014-09-12 2021-01-13 プロメガ コーポレイションＰｒｏｍｅｇａ Ｃｏｒｐｏｒａｔｉｏｎ 内部タンパク質タグ

Also Published As

Publication number Publication date
EP4169935A1 (en) 2023-04-26
US20230342826A1 (en) 2023-10-26
EP4177261A1 (en) 2023-05-10
US9797889B2 (en) 2017-10-24
EP3783011B1 (en) 2022-09-21
EP3783011A1 (en) 2021-02-24
SG11201507306VA (en) 2015-10-29
PL2970412T3 (pl) 2022-11-14
JP2020097597A (ja) 2020-06-25
US11493504B2 (en) 2022-11-08
JP2023055734A (ja) 2023-04-18
US9797890B2 (en) 2017-10-24
KR20150129721A (ko) 2015-11-20
JP2024167207A (ja) 2024-12-03
IL240985A0 (en) 2015-11-30
IL286816B (en) 2022-09-01
KR102675860B1 (ko) 2024-06-20
US20250045806A1 (en) 2025-02-06
CA2906063A1 (en) 2014-09-25
JP7532562B2 (ja) 2024-08-13
IL273989A (en) 2020-05-31
AU2020213288A1 (en) 2020-08-27
WO2014151736A1 (en) 2014-09-25
US20200292534A1 (en) 2020-09-17
DK2970412T3 (da) 2022-08-29
JP6654557B2 (ja) 2020-02-26
US20250022022A1 (en) 2025-01-16
AU2018256548B2 (en) 2020-05-14
CA2906063C (en) 2025-10-07
US9869670B2 (en) 2018-01-16
AU2014236949A1 (en) 2015-09-24
BR112015023394A2 (pt) 2017-11-28
US20180313825A1 (en) 2018-11-01
US10288605B2 (en) 2019-05-14
IL273989B (en) 2021-10-31
KR20210036422A (ko) 2021-04-02
US20140363375A1 (en) 2014-12-11
US20160282340A1 (en) 2016-09-29
ES2929362T3 (es) 2022-11-28
AU2014236949B2 (en) 2018-08-02
CN105143249A (zh) 2015-12-09
CN117024548A (zh) 2023-11-10
IL240985B (en) 2020-05-31
AU2020213288B2 (en) 2022-07-07
BR112015023394B1 (pt) 2023-08-29
US12367513B2 (en) 2025-07-22
SG10201601929YA (en) 2016-04-28
JP2016519065A (ja) 2016-06-30
PT3783011T (pt) 2022-10-26
JP7280842B2 (ja) 2023-05-24
ES2926463T3 (es) 2022-10-26
EP2970412A4 (en) 2016-07-27
AU2018256548A1 (en) 2018-11-22
PT2970412T (pt) 2022-09-13
PL3783011T3 (pl) 2022-11-21
DK2970412T5 (da) 2024-10-14
IL286816A (en) 2021-10-31
EP2970412B1 (en) 2022-08-10
US10107800B2 (en) 2018-10-23
US20180306782A1 (en) 2018-10-25
US20140348747A1 (en) 2014-11-27
DK3783011T5 (da) 2024-08-19
US20180196038A1 (en) 2018-07-12
KR20230079494A (ko) 2023-06-07
DK3783011T3 (da) 2022-10-17
US12366572B2 (en) 2025-07-22
US10184936B2 (en) 2019-01-22
AU2014236949C1 (en) 2018-11-29
EP2970412A1 (en) 2016-01-20
US10648971B2 (en) 2020-05-12
US20180095074A1 (en) 2018-04-05

Similar Documents

Publication Publication Date Title
BR112015023394B8 (pt) Sistema e complexo bioluminescente
CY1123419T1 (el) Αντιδραστηρια sirp-αλφα υψηλης συγγενειας
BR112016020897A2 (pt) ?determinação da agressividade de câncer, prognóstico e capacidade de reação a tratamento?
EA201792497A1 (ru) Антитела к gitr для диагностики злокачественной опухоли
BR112016015677A2 (pt) Moléculas de anticorpo isoladas capazes de se ligarem à pd-1 humana, bem como seu método de produção e seu uso, composições farmacêuticas, ácido nucleico, vetor de expressão, célula hospedeira, e método para detecção de pd-1 em uma amostra biológica
ECSP12012272A (es) Proteínas que se unen al tnf-?
GB2526736A (en) Methods, compositions, and kits for nucleic acid analysis
BR112015023108A8 (pt) sistema de acondicionamento de célula bacteriana, método para acondicionamento de uma molécula de ácido nucléico repórter, composição, método para detectar uma presença ou uma ausência de uma célula bacteriana em uma amostra, vetor, método para detectar um transcrito alvo em uma célula, método para detectar a presença de uma célula bacteriana em uma amostra e kit.
BR112017006598A2 (pt) anticorpo de repetições antidipeptídeo derivado de ser humano (dprs)
BR112018010933A2 (pt) anticorpos multiespecíficos
JO3812B1 (ar) أجسام مضادة ترتبط بالمركب الترابطي البشري للموت المبرمج 1 (pd-l1)
BR112015014751A2 (pt) anticorpos anti-tau humanos
DK2831241T3 (da) Kunstige nukleinsyremolekyler til forbedret protein- eller peptidekspression.
EP4297036A3 (en) Method for predicting the off-target binding of a peptide which binds to a target peptide presented by a major histocompatibility complex
MX2016012055A (es) Ensayos de proteinas glicosiladas.
BR112015022548A2 (pt) método de separação de células usando immunorosettes e partículas magnéticas
CY1124491T1 (el) Σωματιδια πολυμερους και χρησεις αυτων
SG10201807867XA (en) Simultaneous detection of target protein and target nucleic acids in a single cell
EP3756687A3 (en) Target peptides for ovarian cancer therapy and diagnostics
EA201291396A1 (ru) Способ детекции молекулярных взаимодействий
BR112015023769A2 (pt) sistemas de instrumento analítico
AR080680A1 (es) Proteinas de union a basigina
WO2015023503A3 (en) Compositions and methods for multimodal analysis of cmet nucleic acids
MX2021001418A (es) Produccion de proteinas heteromultimericas usando celulas de mamifero.
TW201613981A (en) Compositions and methods for the diagnosis of rheumatoid arthritis

Legal Events

Date Code Title Description
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 13/03/2014, OBSERVADAS AS CONDICOES LEGAIS

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: REF. RPI 2747 DE 29/08/2023 QUANTO AO ENDERECO.